Y-Intercept (HK)’s Actinium Pharmaceuticals ATNM Stock Holding History

Y-Intercept (HK)’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-64,909	Closed	-$90.9K	–	1560
2025 Q2	$90.9K	Buy	+64,909	New	+$97.1K	﹤0.01%	1540

Other funds holding ATNM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Y-Intercept (HK)'s ATNM Position: Q3 2025 in Review

Y-Intercept (HK) sold out of Actinium Pharmaceuticals (ATNM) in Q3 2025, closing a stake of 64,909 shares — an estimated $90.9K sold.

Y-Intercept (HK) first reported a position in ATNM in Q2 2025 and held it in 1 quarter. The position peaked at $90.9K in Q2 2025. 61 funds tracked by Wall St. Rank hold ATNM as of Q3 2025.

Y-Intercept (HK) reported no remaining Actinium Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Y-Intercept (HK) sold 64,909 Actinium Pharmaceuticals shares in Q3 2025, an estimated $90.9K.
Y-Intercept (HK) first reported a position in Actinium Pharmaceuticals in Q2 2025 and held it in 1 quarter.
Y-Intercept (HK)'s Actinium Pharmaceuticals position peaked at $90.9K in Q2 2025.
61 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2025.

Based on Y-Intercept (HK)'s 13F filing for Q3 2025, filed 31 Oct 2025.